David Scheinberg

David Scheinberg

Company: Memorial Sloan Kettering Cancer Center

Job title: Chairman


Leveraging Conditional Activation to Provide Targeted Tumor Killing & Guarantee Therapy Safety 1:30 pm

The hostile tumor microenvironment continues to create a barrier to cell therapy efficacy in solid tumors. Use of gating and switch technology is on the rise to generate localized and specific secretion of factors to provide enhanced killing in the solid tumor microenvironment and hinder T-cell exhaustion. Engineering cells to implement a gated switch system…Read more

day: Pre-Conference Workshops

Targets & Off-Targets of TCR-based Therapies 12:00 pm

Liabilities of TCR-based therapies Methods to identify targets Constructs to overcome hurdlesRead more

day: Conference Day One

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.